Editorial	mode	concluded of	n Iuna	12	2000
Editorial	work	concluded of	n June	1.5.	2008.

Annual subscription rates: Croatian Chemical Society members 15.00 , institutions and companies 80.00 .

For the publisher: Nikola Kallay, Editor-in-Chief, Horvatovac 102 a, HR-10001 Zagreb. Editorial office: Horvatovac 102 a, HR-10000 Zagreb. Bank account for Croatia is 2360000-1101387722 Zagrebačka banka (att. to Hrvatsko kemijsko društvo, Zagreb) payable in kuna, equivalent to the mentioned subscription rate. Bank account for foreigners is 2500-840-2400027680-070 Zagrebačka banka (att. to Hrvatsko kemijsko društvo, Zagreb).

Printed by: LASER plus, Brijunska 1a, Zagreb

The Home Page of *Croat. Chem. Acta* including all the Tables of Contents since 1996 and articles in the pdf since 1998 may be found on the www under http://public.carnet.hr/ccacaa/

Parts of the contents of *Croatica Chemica Acta* (e.g. figures or tables) may be reproduced without prior permission, provided reference is made to their source.

Photocopies of the articles are available through The Genuine Article ^(R) delivery program from: Institute for Scientific Information 3501 Market Street
Philadelphia, PA 19104 USA



PLIVA is the European generic pharmaceutical subsidiary of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. Established in 1921 and with headquarters in Zagreb, Croatia, PLIVA is the leading Central and Eastern European pharmaceutical company with a portfolio of more than 1200 products competing in over 30 countries worldwide. PLIVA develops, manufactures and markets both branded generic pharmaceuticals and active pharmaceutical ingredients (APIs), with products including oral solid forms, injectables, creams/ointments, cytostatics and Over-The-Counter (OTC) products. PLIVA is also an emerging participant in the generic biopharmaceutical arena. PLIVA's strength lies in the Company's diversity, professional staff and commitment to providing high-quality products through superior science, low-cost manufacturing and customer service.

RESULTS OF EXPERIENCE, BEST PRACTICES, KNOWLEDGE AND INNOVATIONS www.pliva.com

Dedicated to health





OUR CENTRE OF EXCELLENCE FOR DRUG DISCOVERY IN CROATIA SHOULD BE THE CENTRE OF YOUR ATTENTION

With our recent acquisition in Zagreb, GSK's commitment to attract the best scientific talent in the industry has never been more resolute. GSK's world renowned Centers of Excellence in Drug Discovery attract and grow the world's best R&D talent. And now we have established one in Zagreb, Croatia.

Dedicated exclusively to macrolide drug discovery and development, we will develop new medicines to treat human diseases, and forge relationships with independent research and academic groups during this important work.

We are looking for the best scientific talent in the chemistry field to help us in this new area. So join us in this significant venture. It will be a new step for both of us.

Please contact us at research-centre.zagreb@gsk.com

GSK is proud to promote an open culture, encouraging people to be themselves and giving their ideas a chance to flourish. GSK is an equal opportunity employer.







